Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics

This article was originally published in The Gray Sheet

Executive Summary

Proteomics collaboration with Hitachi and Oracle may include development of diagnostics and therapeutics as well as primary goal of creating a proprietary database to be marketed to other pharmaceutical and biotechnology companies, the firm says. Valued at $185 mil., the alliance to map the human proteome in less than three years will compete with proteomics firm Celera Genomics. Myriad will contribute $82 mil. in technology to the alliance and retain a 50% stake. Electronics firm Hitachi, software company Oracle and investment banking firm Friedli Corporate Finance will contribute $85 mil. in cash, plus $18 mil. in technology

Related Content

UsernamePublicRestriction

Register

MT014782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel